BIND, AstraZeneca partner to develop cancer nanomedicine Accurin

Accurin that leverages BIND’s Medicinal Nanoengineering platform has superior target selectivity and the potential to improve outcomes in patients with oncology, inflammatory diseases and cardiovascular disorders.

BIND president and CEO Scott Minick said, "Our collaboration with AstraZeneca is the first one completed and had very successful results. Due to the advanced nature of this program, we now plan to move an Accurin with optimized therapeutic properties quickly into product development."

The companies will work to carryout investigational new drug-enabling studies of Accurin that resulted from an earlier feasibility program.

Subsequently, AstraZeneca will be responsible for the development and commercialization activities while BIND will carry out manufacturing operations during the development phase.

According to the deal, BIND is eligible for upfront, pre-approval milestone payments worth $69m, regulatory and sales milestones and other payments over $130m in addition to sales based royalties.

AstraZeneca oncology innovative medicines unit head Susan Galbraith said, "Our oncology teams are actively exploring a range of platforms to deliver targeted therapies, with a strategic focus on unlocking the significant potential of nanoparticles as an approach to cancer treatment. We view BIND’s targeted nanomedicines as a leading technology in this field."